Mahindra to pursue engineering actions to address rare earth magnet crisis: Group CFO
The imposition of export restrictions by China on key rare earth magnets has resulted in supply chain bottlenecks, impacting multiple sectors, including the auto industry. The rare earth magnets are essential components across sectors like automobiles and renewable energy.
Also check these Cars
Find more Cars
UPCOMING Mahindra e20 NXT 15 kWh
15 kWh 140 km
140 km
₹ 6 - 8 Lakhs
Alert Me When Launched
UPCOMING Mahindra XUV500 2025 2179 cc
2179 cc Diesel
Diesel
₹ 12 Lakhs
Alert Me When Launched
UPCOMING Mahindra Thar E 75 kWh
75 kWh 400 km
400 km
₹ 25 Lakhs
Alert Me When Launched
UPCOMING Mahindra Global Pik Up 2498 cc
2498 cc Diesel
Diesel
₹ 25 Lakhs
Alert Me When Launched
UPCOMING Mahindra XEV 7e
₹ 21 - 30 Lakhs
Alert Me When Launched
Mahindra BE 6 79 kWh
79 kWh 682 km
682 km
₹ 18.90 Lakhs
Compare
View Offers
PTI has reported that Mahindra has taken steps to build inventory through alternative sources to take care of the problem. "Basis, all the actions we have taken, FY26 is more or less managed. We have to now work on some medium and long-term actions," said Mahindra & Mahindra (M&M) Group Chief Financial Officer Amarjyoti Barua. He also added that this strategy has panned out well for the company so far, and it does not foresee any major risk for the next nine months. "But considering the growth plans we have, we have to think about a much bigger play than what the tactical plays we have done, and that is going to require a lot more engineering effort," Barua further said, while adding that Mahindra's engineers are working on various methods to work out a solution.
Interestingly, Mahindra CFO's comment comes in similar lines to Maruti Suzuki. Last week, Maruti Suzuki stated that its engineers are working to mitigate the rare earth magnet shortage, and there has been no impact on its production so far. Among others, Hyundai Motor India has also stated that it is not facing any production issues due to the shortage of rare earth magnets.
Check out Upcoming Cars in India 2025, Best SUVs in India.
First Published Date:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News18
an hour ago
- News18
EIH Ltd profit falls to Rs 36.88 cr in Q1
Agency: PTI Last Updated: New Delhi, Aug 5 (PTI) EIH Ltd, the flagship company of luxury hotel chain The Oberoi Group, on Tuesday reported a consolidated net profit of Rs 36.88 crore for the June quarter. The company had reported a net profit of Rs 96.75 crore in the year-ago period. It's total income from operations stood at Rs 609.06 crore for the April-June quarter, as against Rs 559.91 crore during the corresponding period of the previous year, as per a regulatory filing. The company's total expenses rose to Rs 452.95 crore during the quarter, from Rs 429.68 crore a year ago. PTI RSN TRB Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
Mint
an hour ago
- Mint
Trump to impose new tariffs on pharmaceuticals in ‘next week or so' — ‘It is going to go to 250%'
US President Donald Trump has announced that new US tariffs on semiconductor and pharmaceutical imports will be imposed 'within the next week or so.' The move is part of the administration's broader strategy to use trade levies to bring manufacturing back to the US and target key economic sectors, PTI reported. In a recent interview on CNBC, Trump outlined his tariff plan. 'We'll be putting an initially small tariff on pharmaceuticals, but in one year — one and a half years, maximum — it's going to go to 150% and then it's going to go to 250% because we want pharmaceuticals made in our country,' he said. The news report said this follows Trump's recent demand that major suppliers of medicines drastically cut costs or face additional, unspecified penalties. The world's largest drugmakers, including Merck & Co. and Eli Lilly & Co., operate scores of manufacturing sites across the globe. Nearly 90% of US biotech companies rely on imported components for at least half of their approved products, according to the Biotechnology Innovation Organization. In addition to imposing tariffs on pharmaceuticals, the president also revealed his plan to target the chip industry by stating, 'We're going to be announcing on semiconductors and chips, which is a separate category.' The Commerce Department has been investigating the semiconductor market since April to set the stage for possible tariffs on an industry that's expected to generate nearly $700 billion in global sales. These levies could lead to a sharp increase in costs for major data centre operators including Microsoft Corp, OpenAI, Meta Platforms Inc and Amazon that plan on investing billions of dollars in advanced semiconductors to propel their artificial intelligence businesses. Unlike some of the administration's previous country-specific tariffs, which have faced court challenges, these new sectoral tariffs have a stronger legal footing. These sectoral tariffs on pharmaceuticals, metals and other industries stem from trade investigations that can last about nine months and are based on national security groups under Section 232 of the Trade Expansion Act. Those so-called reciprocal tariffs are slated to go into effect on Thursday, PTI reported. The Trump administration has already used this authority to impose levies on imports of cars and auto parts as well as steel and aluminum.
Time of India
2 hours ago
- Time of India
Business outlook: Business confidence index jumps to 149.4 in April-June; NCAER survey flags optimism in sales
India's business sentiment saw a sharp uptick in the April-June quarter, with the Business Confidence Index (BCI) rising to 149.4 from 139.3 in the previous quarter, according to the latest Business Expectations Survey by the National Council of Applied Economic Research (NCAER). The index is built on four key components: expectations of overall economic improvement over the next six months, anticipated improvement in firms' financial positions, views on the present investment climate, and whether capacity utilisation is close to or above optimal levels, PTI reported. NCAER noted that more than 60% of respondents expressed positive views across all four parameters. 'The share of positive responses remained above 60% for each component, and every component exhibited an improving trend compared to the previous quarter,' the think tank said. Optimism around production and domestic demand was particularly strong. Around 78.7% of firms said they expect production to rise in the next six months, while 79.1% anticipated an increase in domestic sales. Export sentiment also strengthened, with 66.5% of respondents expecting a rise in outbound shipments of finished goods. Firms were also more positive about their import requirements, with 54.3% expecting an increase in raw material imports, up from 46.1% in the previous quarter—a sign of expected acceleration in domestic manufacturing activity. Nearly 61% of companies surveyed expected pre-tax profits to rise over the next six months, indicating continued buoyancy in business operations. However, this optimism was not reflected in the labour market outlook. Hiring and wage expectations remained unchanged, suggesting a stagnation in employment sentiment. 'With moderation in costs, firms were more optimistic about the next six months,' said NCAER Professor Bornali Bhandari, who led the survey. The survey, conducted in June, covered 479 companies across six major Indian cities. Stay informed with the latest business news, updates on bank holidays and public holidays .
